Showing results (161-170 of 189) with videos related to

Sort By:
Pageof 19
Neurology|April 8, 2026
Effect of Cognitive Reserve on Age at Symptom Onset and Cognitive Decline in Individuals With Dominantly Inherited Alzheimer DiseaseJorge J Llibre-Guerra, Ruijin Lu, Ma Florencia Clarens, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 24, 2022
Pattern and implications of neurological examination findings in autosomal dominant Alzheimer diseaseJonathan Vöglein, Nicolai Franzmeier, John C Morris, et al.
Brain Communications|November 9, 2023
Longitudinal clinical, cognitive and biomarker profiles in dominantly inherited versus sporadic early-onset Alzheimer's diseaseJorge J Llibre-Guerra, Leonardo Iaccarino, Dean Coble, et al.
Neuroimage. Clinical|January 5, 2021
Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer diseaseAylin Dincer, Brian A Gordon, Amrita Hari-Raj, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|March 9, 2019
Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studiesYi Su, Shaney Flores, Guoqiao Wang, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 22, 2021
Modeling autosomal dominant Alzheimer's disease with machine learningPatrick H Luckett, Austin McCullough, Brian A Gordon, et al.
JAMA Neurology|October 16, 2023
Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer DiseaseZahra Shirzadi, Stephanie A Schultz, Wai-Ying W Yau, et al.
Aging Cell|June 9, 2023
Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal-dominant Alzheimer's diseaseStephanie A Schultz, Zahra Shirzadi, Aaron P Schultz, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2025
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trialAustin McCullough, Charles D Chen, Brian A Gordon, et al.
JAMA Neurology|April 29, 2024
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical TrialOlivia Wagemann, Haiyan Liu, Guoqiao Wang, et al.
Pageof 19